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TLRs initiate immune responses by direct detection of molecular motifs that distinguish invading microbes from host cells. Five
intracellular adaptor proteins, each containing a Toll/IL-1R (TIR) domain, are used by TLRs and play key roles in dictating gene
expression patterns that are tailored to the invader. Such gene expression is mediated by transcription factors, and although TIR
adaptor-induced activation of NF-kB and the IFN regulatory factors have been intensively studied, there is a dearth of informa-
tion on the role of TIR adaptors in regulating CREB. In this paper, we describe a role for the TIR adaptor Mal in enhancing
activation of CREB. Mal-deficient murine bone marrow-derived macrophages show a loss in responsiveness to TLR2 and TLR4
ligands with respect to activation of CREB. Mal-deficient cells also fail to express the CREB-responsive genes IL-10 and cyclo-
oxygenase 2 in response to Pam2Cys-Ser-(Lys)4 and LPS. We reveal that Mal-mediated activation of CREB is dependent on
Pellino3 and TNFR-associated factor 6, because CREB activation is greatly diminished in Pellino3 knockdown cells and TNFR-
associated factor 6-deficient cells. We also demonstrate the importance of p38 MAPK in this pathway with the p38 inhibitor
SB203580 abolishing activation of CREB in murine macrophages. MAPK-activated protein kinase 2 (MK2), a substrate for p38
MAPK, is the likely downstream mediator of p38 MAPK in this pathway, because Mal is shown to activate MK2 and inhibition of
MK2 decreases TLR4-induced activation of CREB. Overall, these studies demonstrate a new role for Mal as a key upstream
regulator of CREB and as a contributor to the expression of both pro- and anti-inflammatory genes. The Journal of Immunology,
2011, 186: 4925–4935.
T
hemammalian innate immune system has evolved an array
of pattern-recognition receptors (PRRs) that detect a host
of pathogen-associated molecular patterns or microbial
motif signatures that are absent from host cells (1). PRRs are the
first line of defense in immunity and regulate the inflammatory
response according to the type of threat they encounter. TLRs
have emerged as an important family of transmembrane PRRs and
directly interact with infectious agents via extracellular regions
containing numerous leucine-rich repeats (2, 3). TLRs also pos-
sess a highly conserved intracellular Toll/IL-1R (TIR) domain, so
named because it shares high homology to the intracellular do-
main of the IL-1R family (4, 5). The TIR domain is crucial to TLR
signaling as demonstrated by a mutation in the TIR domain of
TLR4 resulting in loss of responsiveness to LPS (6). The TIR
domains of TLRs allow for their engagement of TIR domain-
containing adaptor proteins that trigger downstream signaling
cascades culminating in complex patterns of gene expression
profiles (7). TLRs tailor quite specific responses to different in-
vading microorganisms and recruit several TIR adaptor proteins to
initiate downstream signaling. With the exception of TLR3, all
TLRs use MyD88 to activate NF-kB, and this defines a MyD88-
dependent pathway (8). MyD88 associates with and activates
members of the IL-1R–associated kinase (IRAK) family that in
turn recruit TRAF6, an E3 ubiquitin ligase that can promote strong
autoubiquitination. IRAK1 is also ubiquitinated in this complex
by members of the Pellino family of E3 ubiquitin ligases (9–11).
The polyubiquitinated forms of IRAK1 and TRAF6 recruit the
mitogen-activated protein 3 kinase TGF-b–associated protein ki-
nase 1 (TAK1) and associated proteins TAK1-binding proteins
1–3 (12). TAK1 becomes phosphorylated, and this promotes
downstream activation of the IkB-kinases and subsequent phos-
phorylation and degradation of IkBs that normally sequester NF-
kB in the cytosol (13). Interestingly, TAK1 can also stimulate
activation of the p38 and JNK MAPK pathways (14).
Although most TLRs can directly engage the above MyD88-
dependent pathway, TLR2 and TLR4 require the bridging adap-
tor MyD88 adaptor-like (Mal) (15, 16) to associate with MyD88
(17, 18) and to trigger its downstream pathway to activate NF-kB.
In contrast, TLR3 does not use MyD88 or Mal but instead directly
recruits the TIR adaptor Toll/IL-1R domain-containing adaptor-
inducing IFN-b (TRIF) to trigger downstream signaling both to
NF-kB and IFN regulatory factor (IRF) transcription factors
(19–21). TLR4 can also engage this MyD88-independent, TRIF-
dependent pathway but requires the bridging adaptor TRIF-
related adaptor molecule (TRAM) to associate with TRIF (22).
In addition to promoting activation of NF-kB, the TRIF-dependent
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pathway is also a key activator of IRF transcription factors, and
the relative roles of the various TIR adaptors in driving activation
of NF-kB and IRF transcription factors has been investigated in-
tensively (23). However, TLRs can also trigger activation of other
transcription factors, and one that is receiving increasing attention
is CREB.
CREB represents the key transcription factor that mediates re-
gulation of gene expression in response to the second messenger
cAMP (24). Stimuli that elevate the latter can activate cAMP-
dependent protein kinase A (PKA) that in turn will phosphorylate
CREB at Ser-133 and thus increase the transactivation potential of
CREB. Various TLRs can also trigger Ser-133 phosphorylation of
CREB, and in association with agents that elevate cAMP, this can
lead to increased CREB-mediated transcription (25, 26). CREB-
responsive genes include proinflammatory ones such as TNF (27,
28) and cyclooxygenase 2 (COX2) (29) and anti-inflammatory
genes such as IL-10 (30). Although some studies have identified
p38 MAPK and its substrate kinases mitogen- and stress-activated
protein kinases (MSKs) (31, 32) and MAPK-activated protein
kinases (MKs) (9, 33, 34) as immediately upstream of CREB, there
is currently no detail on the role of TLR proximal molecules such as
the TIR adaptors in regulation of the CREB pathway. To this end,
we sought to assess the importance of each of the TIR adaptors in
mediating TLR-induced activation of CREB. We demonstrate a key
role for Mal in mediating TLR2 and TLR4 activation of CREB and
induction of CREB-responsive genes. We also dissect the down-
stream effectors of Mal that mediate activation of CREB and reveal
a signaling axis involving Pellino3, TRAF6, p38 MAPK, and
MK2. Thus, to our knowledge, this study represents the first detailed
delineation of the signaling cascade that is used by TLRs in regu-
lation of CREB.
Materials and Methods
Plasmids and reagents
Y86A Mal-hemagglutinin (HA) and Y187A Mal-HA were as described
previously (35). Mal E190A was created using Pfu Turbo (Stratagene, La
Jolla, CA) and the following primers: 59-AGCTGCCTACCCACCTGA-
GCTCCGATTCATGTACT-39 and 59-AGTACATGAATCGGAGCTCAG-
GTGGGTAGGCAGCT-39. MyD88-Flag was provided by Dr. M. Muzio
(Mario Negri Institute, Milan, Italy). TRIF-Flag and TRAM-Flag were gifts
from Dr. K. Fitzgerald (University of Massachusetts Medical School, Worces-
ter, MA). TRAF6 was from Tularik (San Francisco, CA). TK Renilla-
luciferase reporter construct (phRL-TK) was from Promega (Madison,
WI). CREB-luciferase was from BD Biosciences (San Jose, CA). MK2-
DsRed expression plasmid was as described previously (9). MSCV-IRES-
GFP and MSCV encoding HA-tagged mMal were provided by Dr. S.
Miggin (National University of Ireland Maynooth). cAMP, H89, and PGE2
were from Sigma-Aldrich (St. Louis, MO). MK2 inhibitor, SB203580, and
SP600125 were from Calbiochem. Rp-8-CPT-cAMPS (Rp-8) was from
BioLog (Life Science Institute, Bremen, Germany). Pam2Cys-Ser-(Lys)4
(Pam2Cys) was from InvivoGen (San Diego, CA), and LPS Escherichia
coli serotype EH100 was from Alexis.
Anti–phospho-CREB, anti-CREB, anti–phospho-p38, and anti-p38 Abs
were from Cell Signaling Technology (Danvers, MA). Anti–b-actin Ab was
supplied by Sigma-Aldrich. The anti-COX2 Ab was from Thermo Fischer
Scientific (Fremont, CA). Anti-TRAF6 Ab was from Santa Cruz Biotech-
nology (Santa Cruz, CA), and anti-HA Ab was from Covance (Princeton,
NJ).
Cell culture
The human embryonic kidney (HEK)293 cells engineered to stably express
TLR4 receptor, wild-type (WT) murine embryonic fibroblasts (MEFs), and
TRAF6-deficient MEFs (gifts from Prof. A. Bowie, Trinity College Dublin,
Dublin, Ireland) were maintained in DMEM, which was supplemented with
10% (v/v) FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. G418
(500 mg/ml) was used to select for the stably transfected TLR4 cell line.
WT bone marrow-derived macrophages (BMDMs), Mal-deficient, MyD88-
deficient, TRIF-deficient, and TRAM-deficient BMDMs (gifts from Dr. K.
Fitzgerald, University of Massachusetts Medical School) were grown in
RPMI 1640medium supplemented with 2 mM L-glutamine, 10% (v/v) FBS,
and penicillin/streptomycin (100 U/ml and 100 mg/ml, respectively). Cells
were maintained in a 37˚C humidified atmosphere with 5% CO2.
Lentiviral production and transduction
HEK293 T cells were seeded (2 3 105 cells/ml; 3 ml) in 6-well plates and
grown for 24 h to ∼80% confluency. The cells were transfected using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruc-
tions with the packaging plasmid pCMV-dR 8.91 (900 ng), envelope plas-
mid VSV-G (100 ng), sh-pLKO.1 vector (1 mg), and Pellino3 short hairpin
RNA (shRNA) or control shRNA (Sigma-Aldrich): Pellino3 shRNA 59-
GCACTTGCTGATAGCCACTAT-39. The control shRNA is a nontargeting
shRNA vector that encodes for shRNA that does not match to any known
human or mouse gene. The conditioned medium was changed 24 h post-
transfection and replaced with fresh growth medium containing 30% (v/
v) FBS. The cells were then incubated for an additional 24 h. The lentivirus-
containing medium was harvested and stored at 220˚C. Fresh growth
medium containing 30% (v/v) FBS was again added to cells and incubated
for another 24 h. The virus-containing medium was again harvested and
stored for use. U373 cells were seeded (2 3 105 cells/ml; 3 ml) in 6-well
plates and grown for 24 h. The growth medium was then removed and
replaced with fresh medium containing polybrene (8 mg/ml) and 600 ml
lentivirus-containing medium from above. The plates were incubated at
37˚C for 24 h, after which the medium was removed and replaced with
fresh growth medium containing puromycin (5 mg/ml) to select for cells
showing integration of shRNA constructs. Prior to experiments, cells were
selected for another 2–3 wk in the presence of puromycin to continue se-
lection of cells showing stable integration of shRNA constructs.
Retroviral production and transduction
HEK293 T cells were seeded (2 3 105 cells/ml; 3ml) in 6-well plates and
grown for 24 h to ∼80% confluency. The cells were transfected using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions with the packaging vector c (1 mg) and MSCV plasmid (1 mg)
or MSCV-mMal (1 mg). The cells were then incubated for an additional
24 h. The retrovirus-containing medium was harvested and stored at
220˚C. Fresh growth medium containing 30% (v/v) FBS was added to
cells and incubated for another 24 h. The virus-containing medium was
again harvested and stored for use. WT MEFs and TRAF6-deficient MEFs
were seeded (2 3 105 cells/ml; 6 ml) in 25-cm2 flasks and grown for 4 h.
The growth medium was then removed and replaced with fresh medium
containing polybrene (8 mg/ml) and 1 ml retrovirus-containing medium
from above. The flasks were incubated at 37˚C for 48 h prior to experiments.
Quantitative real-time PCR
U373 cells stably transfected with control or Pellino3 shRNAwere seeded
(2 3 105 cells/ml; 3 ml) into 6-well plates and grown for 24 h. Cells were
washed in PBS, and RNA was extracted using Tri-Reagent (Sigma-
Aldrich). After DNase I digestion, cDNA was generated from normalized
RNA using avian myeloblastosis virus reverse transcriptase (Promega).
Samples were assayed by quantitative real-time PCR for levels of Pellino3
cDNA using Brilliant SYBR Green QPCR Master mix (Stratagene). PCR
was conducted with the CFB-322001G Opticon thermal cycler (Bio-Rad).
Reactions were performed using prevalidated primers (Eurofins MWG
Operon): forward Pellino3 59-TGGCCTGATGGATGGACTGA-39, reverse
Pellino3 59-CAGCACGTTGGACTCGTTTTC-39, forward HRPT 59-GGT-
GAAAAGGACCCCACGAA-39, and reverse HPRT 59-GGCGATGTCAA-
TAGGACTCCAGAT-39.
Transfection and luciferase reporter systems
HEK293 cells stably expressing TLR4 were seeded (1.5 3 105 cells/ml;
200 ml) in 96-well plates and grown for 24 h. Cells were then transfected
using Lipofectamine 2000 transfection reagent, with NF-kB firefly lucif-
erase reporter construct (80 ng) or CREB-regulated firefly luciferase (80
ng), constitutively expressed TK Renilla-luciferase reporter construct
(phRL-TK) (40 ng) (Promega Biosciences) and varying amounts of ex-
pression constructs. Total DNA was kept constant (220 ng/well) using the
appropriate empty vector. The activation of the p38 MAPK pathway was
assessed by performing similar transfections using the trans-activator
plasmid pFA-CHOP (1 ng; Stratagene) with firefly luciferase reporter
plasmid pFR-Luc (60 ng), phRL-TK (20 ng), and varying amounts of the
expression constructs. Cell extracts were generated 24 h post-transfection
using Reporter Lysis Buffer (Promega Biosciences), and extracts were
assayed for firefly luciferase and Renilla-luciferase activity using the Lu-
ciferase Assay system (Promega Biosciences) and coelenterazine (0.1 mg/
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ml Insight Biotechnology), respectively. Luminescence was monitored
with the Glomax microplate luminometer (Promega).
Western blot analysis
BMDMs, MEFs (53 105 cells/ml), or HEK293-TLR4 cells (23 105 cells/
ml) were seeded in 6-well plates and grown for 24 h. In some experiments,
cells were transfected, using Lipofectamine, with small interfering RNA
(siRNA) targeting Pellino3 (sense sequence: 59-GCACAGCAUCUCGU-
AUACATT-39) or with control siRNA targeting lamin (20 nM) (Ambion).
Cells were stimulated with various ligands for different time points as
indicated in the figure legends. Cells were washed in 1 ml ice-cold PBS
and lysed in 100 ml Nonidet P-40 lysis buffer (50 mM Tris-HCl [pH 7.5]
containing 150 mM NaCl, 0.5% [w/v] igepal, 50 mM NaF, 1 mM Na3VO4,
1 mM DTT, 1 mM PMSF, and protease inhibitor mixture [leupeptin (25
mg/ml), aprotinin (25 mg/ml), benzamidine (1 mM), and trypsin inhibitor
(10 mg/ml)]). The cell lysates were centrifuged at 12,000 3 g for 10 min,
supernatants were collected, and samples containing equal protein con-
centrations were generated using 43 sample loading buffer (0.125 M Tris-
HCl [pH 6.8] containing 20% [w/v] glycerol, 4% [w/v] SDS, 1.4 M 2-ME,
and 0.0025% [w/v] bromophenol blue). Samples were then resolved by
SDS-PAGE, transferred to nitrocellulose membrane, and probed for im-
munoreactivity using anti–phospho-CREB, phospho-p38, phospho-p65,
COX2, CREB, p38, a-tubulin–, or b-actin–specific Abs. Immunoreactive
bands were detected using the Odyssey Infrared Imaging System from LI-
COR Biosciences, according to the instructions of the manufacturer.
ELISA-based detection of IL-10
BMDMs were seeded (3 3 105 cells/ml; 200 ml) in 96-well plates and
grown for 24 h. Cells were subsequently stimulated with LPS (100 ng/ml)
for 24 h and/or pretreated with various inhibitors as indicated. Conditioned
medium was collected from each well and measured for levels of IL-10 by
sandwich ELISA (using mouse IL-10 DuoSet kits [R&D Systems]).
EMSA
BMDMs were grown in 6-well plates for 24 h. Cells were then stimulated
with LPS or cAMP for various times. Nuclear extracts were generated as
described previously (36). Nuclear protein (10 mg) was incubated with LI-
COR IRDye 700-labeled oligonucleotide containing the CREB binding site
59-AGAGATTGCCTGACGTCAGAGAGCTAG-39 (underlined nucleotides
constitute the binding site) according to the manufacturer’s instructions.
For supershift analysis, CREB polyclonal Ab (1 mg) or nonimmune IgG
was added to the extracts and chilled for 1 h on ice prior to incubation with
labeled oligonucleotide. All incubations were subjected to electrophoresis
on a 4% native polyacrylamide gel for 2 h at 110 V and subsequently an-
alyzed, and images were captured using the Odyssey Infrared Imaging
System (LI-COR Biosciences).
Chromatin immunoprecipitation assay
BMDMs cells were grown to confluency in 90-mm dishes and stimulated
with LPS (100 ng/ml) for 30 min and 4 h. Chromatin immunoprecipitation
(ChIP) assays were performed as previously described with some mod-
ifications (37). Cells were cross-linked with 1% formaldehyde for 10 min
at 37˚C. Isolated nuclei were subjected to four 12-s sonication pulses from
a Bandelin Sonoplus HD2200 at 50% of the total power. This procedure
yielded chromatin fragments of 200–1000 bp. Chromatin preparation ali-
quots were incubated overnight at 4˚C with anti–phospho-CREB Ab (R&D
Systems) or rabbit IgG. The immunoprecipitate was then incubated with
protein A-agarose beads (Upstate Biotechnology, Waltham, MA) and the
Ab/protein/DNA/beads complex was washed and collected for subsequent
reverse cross-linking by overnight incubation at 65˚C. DNA was then
extracted using the QIAquick purification kit (Qiagen), according to the
manufacturer’s instructions. Standard PCR was conducted with specific
primers designed for both IL-10 and COX2 promoter as follows: IL-10, 59-
CAGAAGTTCATTCCGACCAGT-39 and 59-CCTTCCTGGCAAAGGTT-
TTT-39; and COX2, 59-TTGGGGAAAGCCTAAGCGGAA-39 and 59-CA-
GAGTCCTGACTGACTCCT-39. PCR products were then analyzed by 2%
agarose gel electrophoresis.
Confocal microscopy
HEK293 TLR4 cells were seeded (2 3 105 cells/ml) in 4-well chamber
slides (Lab-Tek; Nunc) and grown for 24 h to ∼80% confluency. Cells
were transfected using Lipofectamine 2000 with Mal-CFP and/or MK2-
dsRed (400 ng). Total DNA was kept constant (800 ng/well) using the
appropriate empty vector. Medium was removed, and the cells were gently
washed three times in chilled PBS (500 ml). Cells were then fixed by
addition of 4% (v/v) paraformaldehyde (500 ml) for 20 min. Cells were
washed three times with PBS. An aliquot (500 ml) of DAPI (1.5 mg/ml) in
water was added to each well for 1 min. Cells were mounted with Vec-
tashield hard-set mounting medium (Molecular Probes). Confocal images
were captured using the 363 objective lens on the UV Zeiss 510 Meta
System laser scanning microscope equipped with the appropriate filter sets.
Acquired images were analyzed using the LSM 5 browser imaging soft-
ware.
Statistical analysis
All data are expressed relative to untreated cells and are the means6 SEM
of triplicate determinations from three independent experiments. For
comparison between two groups, one-way ANOVA with the Neuman-
Keuls post hoc test was used. A p value ,0.05 was considered significant.
Results
Overexpression of Mal enhances CREB activation
The roles of TIR adaptors in triggering activation of NF-kB and
IRF transcription factors have been well characterized, but their
involvement in regulating CREB has not been addressed. We
sought to address this deficiency in our understanding of TLR
signaling pathways and our initial studies investigated the ability
of each of the TIR adaptors to activate CREB. Thus, HEK293
cells were transfected with varying amounts of expression con-
structs encoding MyD88, Mal, TRIF, or TRAM and were assessed
for their potential to induce expression of a cotransfected CREB-
regulated reporter (luciferase) gene. The expression of the adap-
tors was confirmed by immunoblotting, but all four adaptors failed
to show a significant induction of CREB-regulated luciferase (Fig.
1A). Given that previous studies have shown that TLR ligands
such as LPS can only increase CREB-mediated transcription in
conjunction with stimuli that elevate cAMP and activate PKA (25,
26), we examined the potential of each of the adaptors to induce
the expression of the CREB reporter gene in the presence of
coexpressed PKA (Fig. 1B). Although PKA alone was sufficient to
activate CREB activation, this was greatly enhanced when PKA
was coexpressed with Mal. Although TRAM also synergized with
PKA in activating CREB, its efficacy was only half of that dis-
played by Mal. In contrast, MyD88 and TRIF failed to show any
statistically significant synergy with PKA. The augmentation of
PKA-induced activation of CREB by Mal was further character-
ized by demonstrating the dose dependent nature of this response
(Fig. 1C).
Mal mediates TLR2- and TLR4-induced activation of CREB
The above overexpression studies showed that Mal is capable of
enhancing the activation of CREB, and this prompted an in-
vestigation into the physiological role of Mal as a mediator of TLR-
induced activation of CREB. Thus, WT, MyD88-deficient, Mal-
deficient, TRIF-deficient, and TRAM-deficient BMDMs were
treated with LPS (100 ng/ml) and cAMP (100 mM) for 30 min, and
activation of CREB was initially determined by assaying CREB
binding to DNA by EMSA (Fig. 2A). LPS, alone or in combina-
tion with cAMP, induced the binding of CREB to DNA in
WT cells. The presence of CREB as part of a complex with DNA
was confirmed by an upward shift in the mobility of the complex
in the presence of an anti-CREB Ab. In Mal-deficient BMDMs,
LPS failed to induce the formation of this CREB–DNA complex
consistent with a role for Mal in mediating LPS-induced activation
of CREB. In contrast, LPS stimulated CREB binding to DNA in
BMDMs lacking MyD88, TRIF, or TRAM, indicating that LPS-
induced activation of CREB can occur in a manner independent of
these adaptors. Given that a prerequisite for activation of CREB is
the phosphorylation of Ser-133, we also characterized LPS-
induced phosphorylation of Ser-133 in the various BMDM cell
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lines to further confirm the varying roles of the adaptors in the
CREB pathway. The adaptor-deficient BMDM cell lines were
stimulated with LPS (100 ng/ml) over various times, and the
phosphorylation status of CREB was examined by immunoblot-
ting using a phospho–Ser-133 specific Ab (Fig. 2B). In WT cells,
LPS-induced phosphorylation of CREB was detectable after 5 min
and was maintained for up to 1 h. The phospho–Ser-133 Ab
detects two bands, with the slower mobility one representing
phospho-CREB and the faster one corresponding to phosphory-
lated ATF-1, a close relative of CREB. In contrast to WT cells,
LPS fails to induce phosphorylation of CREB in Mal-deficient
BMDMs, whereas LPS-induced phosphorylation of CREB was
still evident in MyD88-, TRIF-, and TRAM-deficient cells (Fig.
2B). We also assessed the role of Mal in cosignaling of LPS and
a physiological stimulus that elevates levels of cAMP. For the
latter purpose, we used the PG PGE2 because it is induced by LPS,
and thus, the simultaneous presence of LPS and PGE2 is a likely
scenario in an inflammatory setting. LPS and PGE2 showed strong
synergy in inducing phosphorylation of CREB, and this is lost in
Mal-deficient cells (Fig. 2C). These findings are all consistent with
a key role for Mal in mediating LPS-induced activation of CREB.
Because Mal is also required for TLR2 signaling, immortalized
WT and Mal-deficient BMDMs were also treated with the TLR
ligand Pam2Cys, and lysates were probed for levels of phospho-
CREB (Fig. 2D). Phosphorylated CREB is detectable after 5 min
of Pam2Cys stimulation and increases further at 15 min before
declining at 1 h. BMDMs lacking Mal protein fail to show any
Pam2Cys-induced phosphorylation of CREB, indicating a key role
for Mal in TLR2-mediated activation of CREB.
Mal mediates TLR4-induced expression of CREB-responsive
genes
The above studies suggest that Mal is a key mediator of CREB
activation, and thus, we next examined the role of Mal in regulating
expression of CREB-responsive genes. We focused on il-10 and
cox2 as genes that have been well characterized in terms of being
positively regulated by CREB (29, 30). ChIP was used to char-
acterize the in vivo binding of CREB to the promoters of these
genes. Stimulation of WT BMDMs with LPS promoted the in vivo
binding of CREB to the il-10 promoter as evidenced by anti-
CREB immunoprecipitation of increased levels of the DNA
fragment of the il-10 promoter that contains the CREB-binding
motif (Fig. 3A). In contrast, LPS fails to induce CREB binding to
the il-10 promoter in Mal-deficient BMDMs. The functional
consequence of the Mal-triggered binding of CREB to the il-10
promoter was explored by measuring the expression levels of IL-
10 in response to LPS stimulation in WT and Mal-deficient
BMDMs (Fig. 3B). WT BMDMs showed a 3.5-fold increase in
IL-10 production upon LPS stimulation, and this was modestly
enhanced when cells were cotreated with a cell-permeable analog
of cAMP. Mal-deficient macrophages showed a substantial im-
pairment in IL-10 production in response to LPS in the absence
and presence of cAMP. These findings show that Mal plays a key
role in mediating TLR-4–induced binding of CREB to the il-10
promoter and expression of IL-10.
We also explored the role of Mal in regulating LPS-induced
expression of the CREB-responsive gene cox2. As with the il-10
promoter, we initially confirmed the LPS-induced binding of
CREB to the cox2 promoter in WT BMDMs by ChIP analysis
FIGURE 1. Overexpression of Mal enhances CREB activation. HEK293 cells stably transfected with TLR4 were cotransfected with plasmids encoding
CREB-regulated firefly luciferase (80 ng), constitutively expressed TK Renilla luciferase (40 ng) and MyD88, Mal, TRIF, and TRAM (0, 20, 50, 80, and
100 ng) (A), MyD88, Mal, TRIF, and TRAM (50 ng) in the presence or absence of PKA (0.1 ng) (B), and Mal (0–100 ng) with or without PKA (0.1 ng) (C).
Empty vector pcDNA3.1 was used to normalize the amount of total DNA transfected. Transfected cells were harvested 24 h post-transfection. Cell lysates
were assayed for firefly luciferase activity and normalized for transfection efficiency using Renilla luciferase activity. Data are presented as the mean 6
SEM of three independent experiments. Results were subjected to one-way ANOVA statistical analysis with Neuman-Keuls post hoc test (*p, 0.05, **p,
0.01, ***p , 0.001); cells transfected with PKA versus cells cotransfected with PKA and adaptors.
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(Fig. 3C). This TLR4-induced binding of CREB to the cox2
promoter was not apparent in Mal-deficient BMDMs. The func-
tional importance of this Mal-induced binding of CREB to the
cox2 promoter was emphasized by the LPS-induced expression of
COX2 protein in WT cells being considerably diminished in Mal-
deficient cells (Fig. 3D). The above findings emphasize the im-
portance of Mal in promoting the expression of CREB-responsive
genes.
Pellino3 and TRAF6 are downstream of LPS/Mal in CREB
activation pathway
Having confirmed a key role for Mal in mediating activation of
CREB and promoting induction of CREB-responsive genes, we
next aimed to delineate the downstream signaling molecules used
by Mal in effecting activation of CREB. We have previously
reported that the E3 ubiquitin ligase Pellino3 strongly activates
CREB (9), and given that this activity of Pellino3 is dependent on
its association with the Mal-interacting protein IRAK1, we probed
the potential role of Pellino3 as a downstream mediator of Mal in
its activation of CREB. The ability of Pellino3 to activate CREB
was initially confirmed, and there was some further modest
enhancement of this activation with a cell-permeable analog
of cAMP (Fig. 4A). In contrast, a mutant form of Pellino3 that
contains point mutations in its RING-like domain (Pellino3S
C374A/C377A) proved incapable of activating CREB, demon-
strating that the activation of CREB by Pellino3 is dependent on
the catalytic E3 ubiquitin ligase activity of the latter. To determine
whether Pellino3 is a mediator of TLR-induced activation of
CREB, we initially used one of our previously described models
in which we suppress endogenous expression of Pellino3 using
Pellino3-specific siRNA (9), and we now show siRNA-mediated
knockdown of Pellino3 causes a dramatic decrease in LPS-
induced phosphorylation of CREB in HEK293-TLR4 cells (Fig.
4B). To complement this approach and to directly assess the role
of Mal in CREB activation, U373 cell lines were infected with
lentivirus containing shRNA constructs that specifically target
Pellino3. Cells showing stable integration of the constructs were
puromycin selected over a number of weeks, and quantitative real-
time PCR was used to confirm knockdown of Pellino3 in these
cells (Fig. 4C). These cells showed a strong reduction in the ability
of Mal to induce expression of a CREB-regulated reporter gene
relative to cells that were infected with lentivirus-containing
control shRNA (Fig. 4D). Pellino3 knockdown cells also dis-
played greatly reduced responsiveness to LPS and Pam2Cys in
terms of activation of CREB (Fig. 4E), consistent with major loss
in phosphorylation of CREB (Fig. 4B), and taken together, these
findings strongly support the proposal that Pellino3 is a mediator
of Mal-induced activation of CREB in TLR pathways.
We have previously shown that TRAF6 can act downstream of
Pellino3, and thus, we next assessed the role of TRAF6 in me-
diating activation of CREB. First, overexpression of TRAF6 was
sufficient to cause low activation of basal CREB and strong en-
hancement of cAMP-induced activation of CREB (Fig. 4F). Fur-
thermore, whereas LPS stimulated strong phosphorylation of
CREB in WT MEFs, this effect was totally absent in TRAF6-
deficient MEFs (Fig. 4G), demonstrating that TRAF6 is in-
dispensable for TLR4-induced activation of CREB. To directly
assess the importance of TRAF6 as a mediator of Mal-induced
activation of CREB, WT and TRAF6-deficient MEFs were
transduced with retrovirus encoding or lacking murine Mal.
Transduction of WT MEFs with retrovirus encoding Mal led to
a slight increase in basal phosphorylation of CREB and enhanced
FIGURE 2. Mal mediates TLR2- and TLR4-induced activation of CREB. A, Immortalized BMDMs from WT, MyD88-deficient, Mal-deficient, TRIF-
deficient, and TRAM-deficient mice were stimulated with LPS (100 ng/ml) and/or cAMP (100 mM) for 30 min. Nuclear extracts (10 mg protein) were
generated and assayed for binding to an oligonucleotide containing a consensus CREB-binding motif by EMSA. Nuclear extracts from WT cells stimulated
for 30 min with LPS were also preincubated with anti-CREB or nonimmune (IgG) Ab before assaying CREB-DNA–binding activity. B, Immortalized
BMDMs from WT, MyD88-deficient, Mal-deficient, TRIF-deficient, and TRAM-deficient mice were treated for the indicated times with LPS (100 ng/ml).
C, WT and Mal-deficient BMDMs were treated with/without LPS (100 ng/ml) and/or PGE2 (100 ng/ml) for 30 min. D, WT and Mal-deficient BMDMs were
treated for the indicated times with Pam2Cys (100 ng/ml). Cell lysates were subjected to SDS-PAGE and analyzed by Western immunoblotting using anti–
phospho-CREB and anti-CREB Abs. Data are representative of three independent experiments.
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LPS-induced phosphorylation of CREB (Fig. 4H). In contrast, Mal
failed to affect basal or LPS-induced phosphorylation of CREB
in TRAF6-deficient cells, indicating a key role for TRAF6 as
a mediator of Mal-induced activation of CREB. Mal contains a
TRAF6-binding motif/activation site (38), and we next explored
the effect of mutating this site (E190A) on the ability of Mal to
activate CREB. However, the Mal E190A mutant mirrored the
ability of WT Mal to activate CREB (Fig. 4I). To demonstrate
specificity of action for Mal in this assay, mutation of tyrosine
residue 88 or 187, critical residues for Mal signaling (35), abol-
ishes the ability of Mal to activate CREB. It is interesting that the
E190 mutant is capable of interacting with TRAF6, no longer
activates NF-kB (38), but can still activate CREB. This suggests
that although Mal can interact with TRAF6 and activate both NF-
kB and CREB, the structural features of Mal that are required for
these pathways are not identical.
Mal activation of CREB is p38 MAPK dependent
We have previously demonstrated that TRAF6 and p38 MAPK act
as downstream mediators of Pellino3-induced activation of CREB
(9), and in an effort to further map the signaling cascade used by
Mal in activation of CREB, we characterized the role of p38
MAPK in this pathway. We initially probed the role of Mal in
mediating LPS-induced activation of p38 MAPK in our BMDM
experimental system. The activation of p38 MAPK was assayed
by measuring the dual phosphorylaton of the threonine and tyro-
sine residues in its activation motif. LPS induced strong phos-
phorylation of p38 MAPK pathway in a time-dependent manner in
WT BMDMs, but this was greatly diminished in Mal-deficient
cells, demonstrating a key role for Mal in activation of the p38
MAPK pathway (Fig. 5A, densitometric analysis shown in the
right panel). The role of p38 MAPK as a mediator in activating
CREB in response to LPS was next examined. The p38 MAPK
inhibitor SB203580 ablated the ability of LPS to induce phos-
phorylation of CREB, whereas the JNK inhibitor SP600125 was
without effect (Fig. 5B), demonstrating a specific role for p38
MAPK in activation of CREB. This was further corroborated by
a study showing that SB203580 blocked LPS induction of the
CREB-responsive protein IL-10, whereas again, SP600125 was
ineffective (Fig. 5C). Given that the findings above had also im-
plicated a role for TRAF6 in mediating Mal-induced activation of
CREB, we also sought to confirm that TRAF6 is an upstream
regulator of p38 MAPK in this pathway. Indeed, this is demon-
strated by LPS inducing strong time-dependent phosphorylation of
p38 MAPK in WT MEFs, whereas this is completely absent in
TRAF6-deficient cells (Fig. 5D).
Mal-induced activation of CREB is MK2 dependent
We finally aimed to define the downstream effector kinase used by
p38 MAPK in mediating Mal-induced activation of CREB. Given
that PKA is the classical CREB kinase, we initially assessed the
effects of the PKA inhibitor H89 on activation of CREB. Pre-
treatment of BMDMs with H89 attenuated the LPS induced
phosphorylation of CREB (Fig. 6A) and also reduced the expression
of IL-10 in response to LPS (Fig. 6B), suggesting a role for PKA.
However, we were mindful that H89 has also been reported to act as
an inhibitor of MSK2, a known upstream kinase of CREB, and
thus, we also used Rp-8-CPT-cAMPs (Rp-8), a more selective in-
hibitor of PKA (39). However, Rp-8 failed to affect the ability of
LPS to induce phosphorylation of CREB (Fig. 6C) or expression of
IL-10 (Fig. 6D). As a positive control for the inhibitory activity of
Rp-8, the latter was shown to cause a dose-dependent inhibition of
cAMP-induced activation of CREB (Fig. 6E). These findings
suggest that the inhibitory effects described above for H89 are not
attributable to targeting of PKA but instead more likely represents
an inhibitory effect on MSKs.
We also noted that the inhibitory effects of H89 on LPS-induced
activation of CREB and induction of IL-10 were incomplete,
FIGURE 3. Mal mediates TLR4-induced expression of CREB-responsive genes. A and C, WT and Mal-deficient BMDMs were stimulated with LPS (100
ng/ml) for indicated times. Cells were then fixed in formaldehyde, and sonicated nuclear lysates were immunoprecipitated with an anti–phospho-CREB or
rabbit IgG. Input DNA and immunoprecipitated chromatin were analyzed by 37 cycles of PCR with primers specific for promoters of genes encoding IL-10
(A) and COX2 (C). Results are representative of two independent experiments. B, BMDMs from WT and Mal-deficient mice were seeded into 96-well
plates and stimulated with LPS (100 ng/ml) and/or cAMP (100 mM) for 24 h. Supernatants were analyzed for IL-10 production using sandwich ELISA.
Data are presented as the mean 6 SEM of three independent experiments. Results were subjected to one-way ANOVA statistical analysis with Neuman-
Keuls post hoc test (*** p , 0.001); WT cells treated with ligand(s) versus Mal-deficient cells treated with ligand(s). D, WT and Mal-deficient BMDMs
were treated with/without LPS (100 ng/ml) and/or PGE2 (100 ng/ml) for 30 min and 4 h. Cell lysates were subjected to SDS-PAGE and analyzed by
Western immunoblotting using anti-COX2 and anti–a-tubulin Abs. Data are representative of three independent experiments.
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suggesting a contributory role for other kinases in addition to
MSKs. MKs have also been described as CREB kinases (40), and
indeed, we have previously shown that Pellino3 can activate MK2
in a p38 MAPK-dependent manner (9). The availability of a spe-
cific MK2 inhibitor facilitated an assessment of the potential role
of MK2 in a mediator in the present pathways. Indeed, the MK2
inhibitor showed some inhibitory effects on LPS-induced phos-
phorylation of CREB (Fig. 6F) and expression of IL-10 (Fig. 6G),
suggesting a role for MK2 in this CREB pathway. However, it was
necessary to show that Mal was capable of stimulating activation
of MK2. The latter is a known substrate of p38 MAPK and in
unstimulated cells is found primarily in the nucleus because of
a functional nuclear localization signal and masking of its nuclear
export signal (41, 42). However, active p38 MAPK can phos-
phorylate MK2, which exposes the nuclear export signal leading to
the shuttling of the p38/MK2/MK3 complex to the cytoplasm.
Thus, as an index of MK2 activation, we sought to probe whether
Mal could promote nuclear-cytoplasmic shuttling of MK2.
HEK293 cells were transfected with MK2-DsRed (previously de-
scribed in Ref. 9) in the absence or presence of Mal-CFP, and the
subcellular localization of the proteins was examined using con-
focal microscopy (Fig. 6H–J). The expression of Mal-CFP (shown
as green to differentiate from DAPI) manifested as very distinct
staining at the plasma membrane in the absence (Fig. 6H) or
presence of MK2 (Fig. 6J). However, when transfected alone,
MK2-DsRed was found predominantly in the nuclei of cells (Fig.
FIGURE 4. Pellino3 and TRAF6 are downstream effectors of LPS/Mal induced activation of CREB. A, HEK293 TLR4 cells were cotransfected with
CREB-regulated firefly luciferase (80 ng), TK Renilla luciferase (40 ng), and a construct encoding Pellino3S or Pellino3S C374A/C377A (0–100 ng). Cell
lysates were subsequently assessed for normalized firefly luciferase activity. B, HEK293 TLR4 cells were transfected with Pellino3-specific siRNA or
control Lamin siRNA (CT) (20 mM) and incubated at 37˚C for 48 h. Cells were treated with LPS (100 ng/ml) for indicated times, and cell lysates were
generated and subjected to Western immunoblotting using anti–phospho-CREB and anti-CREB Abs. C, U373 cells were stably transduced with control or
Pellino3-specific shRNA. RNAwas extracted, and cDNAwas generated and assayed for Pellino3 expression using quantitative PCR. Data represent mean
6 SEM of two independent experiments. D and E, U373 cells, stably transduced with control or Pellino3-specific shRNA, were cotransfected with CREB-
regulated firefly luciferase (80 ng) or TK Renilla luciferase (40 ng) in the absence or presence of Mal (50 ng). Cells were treated, as indicated, with cAMP
(100 mM), LPS (100 ng/ml), or Pam2Cys (100 ng/ml) for 6 h, after which lysates were assayed for normalized firefly luciferase activity. F and I, HEK293
TLR4 cells were cotransfected with TK Renilla luciferase (40 ng), CREB-regulated firefly luciferase (80 ng), and TRAF6 (0–100 ng) (F) or Mal,
MalE190A, MalY86A, or MalY187A (0–100 ng) (I) with and without cAMP treatment. Cell lysates were subsequently assessed for normalized firefly
luciferase activity. G, MEFs from WT and TRAF6-deficient mice were seeded in 6-well plates (5 3 105 cells/ml) and grown for 24 h or were first
transduced with a MSCV murine retroviral plasmid or MSCVencoding mMal-HA for 48 h before seeding in 6-well plates (H). Cells were then stimulated
with LPS (100 ng/ml) for the indicated time periods. Cell lysates were generated and subjected to Western blotting using anti–phospho-CREB, anti-CREB,
anti-HA, anti-TRAF6, and anti–b-actin Abs. Results are indicative of three independent experiments. All luciferase data represent mean 6 SEM of three
independent experiments (except E, which is the mean 6 SEM of two independent experiments). Results were subjected to one-way ANOVA statistical
analysis with Neuman-Keuls post hoc test (*p , 0.05, **p , 0.01, ***p , 0.001, ns, nonsignificant); cells treated with cAMP versus cells treated with
cAMP and transfected with Pellino3S or Pellino3S C374A/C377A (A); cells stably expressing control shRNA versus cells stably expressing Pellino3
shRNA both transfected with Mal and treated with cAMP (D); and cells treated with cAMP versus cells treated with cAMP and transfected with Mal,
MalE190A, MalY86A, or MalY187A (I).
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6I), whereas it redistributed to the cytoplasm in those cells showing
coexpression of Mal-CFP (Fig. 6J). This demonstrates that Mal is
capable of promoting downstream activation of MK2 and, in
conjunction with the above MK2 inhibitor studies, suggests that
MK2 is a likely mediator in Mal-induced activation of CREB.
Discussion
TIR adaptor proteins play key roles in defining the intracellular
signaling pathways and gene expression profiles that are triggered
by distinct TLRs. One of the challenges to our complete un-
derstanding of TLR biology is a lack of appreciation of how varying
gene expression patterns can be generated in response to different
pathogens and TLRs, and yet, the intracellular signaling pathways
tend to be shared extensively by the various TLRs. In addition, all
of the signaling pathways that are used by TLRs are ultimately
triggered by TIR adaptor molecules, and thus, it is vitally important
to define all of their downstream signaling cascades. To date, most
research effort has focused on the ability of the adaptors to promote
activation of two major families of transcription factors namely
NF-kB and IRFs. However, other transcription factors are un-
doubtedly critical to TLR function, and the current study focused
on CREB and the role of TIR adaptors, especially Mal, in regu-
lating its activation.
The initial findings in this study highlighted the predominant
role of Mal in promoting activation of CREB. Although the over-
expression studies suggest that TRAM may also be capable of
activating CREB, this may not be relevant in a physiological setting
because LPS can still induce activation of CREB in cells lacking
TRAM. In the case of Mal, it strongly enhances activation of
CREB, and it is essential for LPS-induced activation of CREB
because cells that lack Mal are unresponsive to LPS in terms of
CREBactivation. Interestingly,Mal alone is a veryweak activator of
CREB and requires a stimulus that can increase levels of cAMP
and/or activate PKA. This is hardly surprising because it is already
known that LPS can only induce activation of CREB and increase its
transactivation potential in the presence of a cAMP stimulus (25,
26). In a physiological setting, there are multiple G protein-coupled
receptors that can enhance levels of cAMP and potentially integrate
with TLR signaling, and some of the lead candidates that may fill
this role in an inflammatory setting are PGs. The latter are syn-
thesized in response to inflammatory stimuli such as LPS, and this
process is generally facilitated by the induction of the enzyme
COX2, a key component in the biosynthetic pathway leading to PG
production. Indeed, in the current study, we show a critical role for
Mal in mediating LPS-induced expression of COX2. Thus, the
Mal-induced CREB pathway described in the current study may
FIGURE 5. LPS/Mal induced activation of CREB is p38 MAPK dependent. A, Immortalized BMDMs fromWTand Mal-deficient mice were treated with
or without LPS (100 ng/ml) for the indicated time periods. Cell lysates were collected and subsequently subjected to Western immunoblotting using anti–
phospho-p38, anti-p38, and b-actin Abs. Densitometric analysis (right panel) was used to calculate intensity of phospho-p38 staining (normalized to total
p38), and the data are represented relative to unstimulated cells. B and C, Immortalized BMDMs from WT mice were pretreated for 30 min with SB203580
(10 mM) or SP600125 (10 mM) and then stimulated with LPS (100 ng) for indicated times or 24 h (C). B, Cell lysates were collected and subjected to
Western immunoblotting analysis using anti–phospho-CREB, anti-CREB, and anti–b-actin Abs. C, Conditioned media from cells were assayed for IL-10
levels by sandwich ELISA. Data are presented as the mean 6 SEM of three independent experiments and subjected to one-way ANOVA statistical analysis
with Neuman-Keuls post hoc test (*p, 0.05, LPS-treated cells versus LPS-treated cells pretreated with SB203580). D, MEFs fromWTor TRAF6-deficient
mice were treated with or without LPS (100 ng/ml) for the indicated time periods. Cell lysates were collected and subsequently subjected to Western
immunoblotting using anti–phospho-p38, anti-p38, and b-actin Abs. Data are representative of three experiments.
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facilitate a positive feedback system in dysregulated inflammatory
responses where Mal can activate CREB that will induce COX2,
and this will lead to PG production. The latter, including molecules
such as PGE2, can then feed back on the cells, promoting increased
levels of cAMP and activation of PKA that will then synergize with
the Mal pathway and promote further activation of CREB and in-
duction of CREB-responsive genes. Indeed, the current study
demonstrates the synergy of LPS and PGE2 in relation to activation
of CREB, and this is lost in Mal-deficient cells.
It is interesting to note that although LPS and Mal are incapable
of promoting CREB-mediated transcription in the absence of
a cAMP stimulus, they can induce Ser-133 phosphorylation of
CREB without a costimulus. This is consistent with the notion that
Ser-133 phosphorylation of CREB is insufficient to promote its
activation, and it may require additional modifications and/or
associations with ancillary proteins (24), and it will be of in-
terest to further explore how Mal may be able to facilitate these
modifications and/or associations.
To our knowledge, the present study also highlights for the first
time the key role of Mal in regulating the expression of anti-
inflammatory genes. To date, most studies on Mal have focused
on its role in the induction of proinflammatory genes and more
recently on its negative regulatory effects on IFN production (43).
We now report that Mal is also a crucial mediator in the induction
of the anti-inflammatory protein IL-10 via its ability to trigger
activation of CREB. This raises the intriguing notion that Mal may
be a crucial modulator in controlling the magnitude of the in-
flammatory response, and indeed, this is supported by studies
showing that some polymorphic forms of Mal can bestow pro-
tection to infectious diseases and the autoimmune disease sys-
temic lupus erythematosus (44–46), and it will be of interest to
explore the regulation of the CREB pathway by these forms of
Mal. The dualist role of Mal in mediating the induction of pro-
and anti-inflammatory genes also warrants further investigation
into the signaling pathways that are used by Mal in promoting
these opposing responses. Although NF-kB is obviously central to
its induction of proinflammatory genes, this study offers the
CREB pathway as a crucial mediator of its potential to induce
anti-inflammatory proteins such as IL-10. Findings from this study
also highlight the intriguing notion that the structural requirements
FIGURE 6. Mal-induced activation of CREB is MK2 dependent. A–D, F, and G, Immortalized BMDMs from WT mice were pretreated with H89 (20
mM) (A, B) for 30 min Rp-8-CPT-cAMPS (100 mM) (C, D) for 30 min, or MK2 inhibitor (20 mM) (F, G) for 1 h and then stimulated with LPS (100 ng/ml)
for the indicated time periods or 24 h (B, D, G). A, C, and F, Cell lysates were collected and subjected to Western immunoblotting using anti–phospho-
CREB, anti-CREB, and anti–b-actin Abs. B, D, and G, Conditioned media from cells were assayed for IL-10 levels by sandwich ELISA. E, HEK293 TLR4
cells were transfected with CREB-regulated firefly luciferase (80 ng) and TK Renilla luciferase (40 ng). Transfected cells were left overnight and then
pretreated with/without Rp-8-CPT-cAMPS (100 or 300 mM) for 30 min and then stimulated with cAMP (100 mM) for 6 h. Cell lysates were assayed for
firefly luciferase activity and normalized for transfection efficiency using Renilla luciferase activity. H–J, HEK293 cells were transfected with Mal-CFP
(H), MK 2-DsRed (I), or Mal-CFP and MK2-DsRed (J). Confocal images were captured using the363 objective (oil immersion) on the UV Zeiss 510 Meta
System laser scanning microscope equipped with the appropriate filter sets and analyzed using the LSM 5 browser imaging software. DAPI staining of the
nuclei is also included. Scale bars, 20 mm. All data are representative of three independent experiments. Luciferase and ELISA data are presented as the
mean 6 SEM of three independent experiments and were subjected to one-way ANOVA statistical analysis with Neuman-Keuls post hoc test (**p , 0.01,
*** p , 0.001, ns, nonsignificant); LPS-treated cells versus LPS-treated cells pretreated with H89 (B), Rp-8 (D), or MK2 inhibitor (G); cAMP-treated cells
versus cAMP-treated cells pretreated with 100 or 300 mM Rp-8 (E).
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of Mal for activating the CREB pathways may differ from those
essential for the NF-kB pathway. Thus, the Mal E190A mutant
mimics its WT counterpart in being capable of strongly activating
CREB, whereas it no longer activates NF-kB and indeed can act as
a dominant negative for the latter. This suggests that it may be
possible to target Mal to differentially regulate its pro- and anti-
inflammatory effects, and thus, Mal may act as a valuable target to
modulate the inflammatory response.
The studies described presently propose a signaling cascade
involving Pellino3, TRAF6, p38 MAPK, and MK2 that mediates
the Mal-induced activation of CREB. CREB has been reported to
act as a substrate for a plethora of kinases (24). Although PKA is
the key kinase used in response to elevation of cAMP, in the
context of an inflammatory stimulus, the MSKs and MKs are the
lead candidates as the immediate upstream CREB kinases. In the
current study, we exclude a role for PKA, and our data are con-
sistent with contributory roles for both of the latter classes of
kinases. Given that other TIR adaptors such as MyD88 can also
trigger activation of these downstream components, it is somewhat
surprising that Mal at this stage appears to be unique among the
TIR adaptors as a mediator on the CREB pathway. However, this
may reflect a situation where Mal may stimulate an additional
process that is not promoted by the other adaptors. One can spec-
ulate that such a process may facilitate some additional modification
of CREB that is required for its activation. Indeed, in addition to
phosphorylation, CREB is subject to a variety of post-translational
modifications including acetylation, ubiquitination, as well as
sumoylation (24), and it will be interesting to assess whether Mal
can regulate such processes. Alternatively, Mal may uniquely
stimulate a process that facilitates the interaction of CREB with
proteins that are essential for its activity. These could include co-
activator proteins such as CREB-binding protein (24). Irrespective
of the exact mechanism, the current study emphasizes a new role for
Mal as a key mediator in TLR-induced activation of CREB. It also
suggests that Mal may be an important signaling molecule for
dictating the balance of proinflammatory versus anti-inflammatory
gene expression and warrants further investigation into how Mal
may be targeted to control dysregulated inflammatory responses.
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